Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

An anonymous reader shared this report from CNBC: Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly … [+1134 chars]

Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial
Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial
Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute
Der Dollar zittert mit dem Fernsehduell
Treasury yields a touch higher as traders await PCE inflation data

Apple Vision Pro Launches In First Countries Outside the US
CNBC Daily Open: Presidential debate